INNATE PHARMA SA (IPHYF:OTCMKTS)
$1.65 -0.6 (-26.6667%)
Analysed INNATE PHARMA SA (IPHYF:OTCMKTS) News Sources
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
13-04-2026
yahoo.com
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
13-04-2026
yahoo.com
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
17-04-2026
yahoo.com
Innate Pharma to Participate in the D. Boral Capital Global Conference
23-04-2026
yahoo.com
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
27-04-2026
yahoo.com
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
06-05-2026
yahoo.com
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
12-05-2026
yahoo.com
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
13-05-2026
yahoo.com
Innate Pharma to participate in the Jefferies Global Healthcare Conference
19-05-2026
yahoo.com
Outcome of Innate Pharma’s 2026 Annual General Meeting
22-05-2026
yahoo.com
What is the current price of INNATE PHARMA SA (IPHYF:OTCMKTS)?
The current price of INNATE PHARMA SA (IPHYF:OTCMKTS) is $1.65.
INNATE PHARMA SA (IPHYF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of INNATE PHARMA SA (IPHYF:OTCMKTS) since the previous trading day is $-0.6.
INNATE PHARMA SA (IPHYF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of INNATE PHARMA SA (IPHYF:OTCMKTS) since the previous trading day is -26.6667%.
What is the most recent average sentiment score for INNATE PHARMA SA (IPHYF:OTCMKTS)?
The most recent average sentiment score for INNATE PHARMA SA (IPHYF:OTCMKTS) is 66 out of 100.
What is the most recent average sentiment for INNATE PHARMA SA (IPHYF:OTCMKTS)?
The most recent sentiment for INNATE PHARMA SA (IPHYF:OTCMKTS) is .
SEC-8K** Filing Available For INNATE PHARMA SA (IPHYF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.